CinDome Pharma Announces Enrollment Completion in the envision3D Phase 2 Clinical Trial of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis
Deudomperidone represents the first potential therapeutic for the long-term treatment of gastroparesis.
CinDome Pharma Announces First Patient Dosed in the envisionGI Phase 2 Clinical Trial of Deudomperidone (CIN-102) for the Treatment of Idiopathic Gastroparesis
CinDome announces that the first participant has been dosed in the envisionGI Phase 2 clinical trial of deudomperidone (CIN-102) in adults with idiopathic gastroparesis.
CinFina Pharma Presents Positive Phase 1 Study Results in Poster Session for CIN-109 and in Late-Breaking Poster for CIN-110, Demonstrating the Potential of Next-Generation Mechanisms at ObesityWeek® 2024
CinFina Pharma Presents Positive Phase 1 Study Results in Poster Session for CIN-109 and in Late-Breaking Poster for CIN-110.